XT
LCTX icon

XTX Topco’s Lineage Cell Therapeutics LCTX Stock Holding History

XTX Topco’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.5K Buy
58,365
+25,997
+80% +$35.9K ﹤0.01% 3607
2026
Q1 		$51.1K Sell
32,368
-9,913
-23% -$16.7K ﹤0.01% 3312
2025
Q4 		$70.6K Buy
+42,281
New +$73.2K ﹤0.01% 2743
2025
Q3 		– Sell
-94,054
Closed -$85.3K – 2934
2025
Q2 		$85.3K Buy
94,054
+50,876
+118% +$30.2K ﹤0.01% 1912
2025
Q1 		$19.5K Buy
+43,178
New +$25.3K ﹤0.01% 2141
2024
Q3 		– Sell
-61,515
Closed -$61.3K – 2360
2024
Q2 		$61.3K Buy
+61,515
New +$67.9K 0.01% 1485
2024
Q1 		– Sell
-27,037
Closed -$29.5K – 2107
2023
Q4 		$29.5K Buy
+27,037
New +$29.6K 0.01% 1311
2022
Q4 		– Sell
-72,807
Closed -$82K – 1329
2022
Q3 		$82K Buy
72,807
+49,255
+209% +$72.3K 0.02% 978
2022
Q2 		$37K Buy
+23,552
New +$31.1K 0.02% 773
2022
Q1 		– Sell
-13,429
Closed -$33K – 828
2021
Q4 		$33K Buy
+13,429
New +$31.4K 0.02% 601

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

XTX Topco's LCTX Position: Q2 2026 in Review

XTX Topco increased its Lineage Cell Therapeutics (LCTX) stake by 80% in Q2 2026, buying an estimated $35.9K and bringing the position to 58,365 shares worth $76.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3607.

XTX Topco first reported a position in LCTX in Q4 2021 and has held it in 10 quarters since. The position peaked at $85.3K in Q2 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • XTX Topco held 58,365 shares of Lineage Cell Therapeutics worth $76.5K as of Q2 2026.
  • XTX Topco bought 25,997 Lineage Cell Therapeutics shares in Q2 2026, an estimated $35.9K.
  • Lineage Cell Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3607 holding.
  • XTX Topco first reported a position in Lineage Cell Therapeutics in Q4 2021 and has held it in 10 quarters since.
  • XTX Topco's Lineage Cell Therapeutics position peaked at $85.3K in Q2 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.